Session Type: ACR Concurrent Abstract Session
Session Time: 4:30PM-6:00PM
Background/Purpose: Prolonged endogenous activation of fibroblasts is a major hallmark of fibrosing disorders such as Systemic Sclerosis (SSc). It results in tissue fibrosis, organ failure and a high morbidity and mortality. Trimethylation of H3 at lysine residue K27 (H3K27me3) is an epigenetic mark that mediates gene repression. H3K27me3 was recently identified as an important negative regulator of fibroblast activation . Demethylation of H3K27me3 is mediated by JMJD3. JMJD3 inhibitors are currently being tested as therapeutic strategies in malignant diseases. The aim of this study is to characterize the role of JMJD3 in fibroblast activation and to explore JMJD3 as a potential drug target in SSc.
Methods: The expression of JMJD3 was analyzed by qPCR, IF and Western blot in patients with SSc, healthy controls and in experimental fibrosis. siRNA mediated knockdown and pharmacologic inhibition by GSKJ4 were used to target JMJD3. In vivo, the effects of JMJD3-inhibiton were analyzed in the mouse model of bleomycin-induced dermal fibrosis, in the model of Topoisomerase-I-induced (TopoI) fibrosis and in a mouse model with adenoviral overexpression of a constitutively active transforming growth factor beta (TGF-β) receptor type 1 (TBR
Results: The expression of JMJD3 was increased in the skin of SSc patients as compared to healthy volunteers. Accumulation of JMJD3 was also observed in experimental models of SSc. TGF-β potently induced the expression of JMJD3 in vitro and in vivo. Pharmacologic inhibition and siRNA mediated knockdown of JMJD3 strongly upregulated the levels of H3K27me3 in vitro and in vivo. Inhibition of JMJD3 reverted the activated fibroblast phenotype in SSc fibroblasts and persistently decreased the expression of contractile fibers and of α-smooth muscle actin. Secretion of collagen was reduced upon inhibition of JMJD3. JMJD3- inhibition also resulted in a significant down-regulation of the profibrotic transcription factor Fra-2 in vitro and in vivo. Overexpression of Fra-2 in JMJD3-knockdown fibroblasts restored the profibrotic effect of JMJD3. In vivo, inhibition of JMJD3 ameliorated fibrosis in bleomycin-, TopoI- and TBR
To cite this abstract in AMA style:Bergmann C, Brandt A, Dees C, Zhang Y, Lin NY, Chen CW, Mallano T, Liang R, Kam PS, Distler O, Schett G, Distler JH. Jumonji Domain Containing Protein 3 (JMJD3) As a Novel Epigenetic Mechanism of Fibroblast Activation By Regulation of Fra-2 [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/jumonji-domain-containing-protein-3-jmjd3-as-a-novel-epigenetic-mechanism-of-fibroblast-activation-by-regulation-of-fra-2/. Accessed October 18, 2021.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/jumonji-domain-containing-protein-3-jmjd3-as-a-novel-epigenetic-mechanism-of-fibroblast-activation-by-regulation-of-fra-2/